Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05576662 · ClinicalTrials.gov registry record · Phase 2
Paxlovid for Treatment of Long Covid
A Phase 2 study, sponsored by Stanford University.
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT05576662: Completed Phase 2 study, sponsored by Stanford University.
NCT05576662 is a Phase 2 study that has completed, run by Stanford University. The registered enrollment target is 168 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05576662, a Phase 2 study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid. Participants will have 5 planned visits to the study clinic over 15 weeks and will take the drug (or placebo) for the first 15 days. This study uses the term post-acute sequelae of SARS-CoV-2 (PASC), which is another name for "Long Covid."
Interventions
- DRUG Placebo
- DRUG Ritonavir
- DRUG Nirmatrelvir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2022-11-08 |
| Est. Completion | 2023-09-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05576662
The ClinicalTrials.gov registry entry for NCT05576662 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stanford University, which has 1,744 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05576662 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05576662 about?
NCT05576662 is a clinical study titled "Paxlovid for Treatment of Long Covid". The purpose of this study is to compare whether being treated with nirmatrelvir plus ritonavir for 15 days works better than being treated with placebo plus ritonavir to reduce severe symptoms of Long Covid. Participants will have 5 planned visits to the study clinic over 15 weeks and will take the...
What is the current status of trial NCT05576662?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2022-11-08. Estimated completion is 2023-09-12.
What interventions are being tested in trial NCT05576662?
The interventions under investigation include: Placebo (DRUG), Ritonavir (DRUG), Nirmatrelvir (DRUG).
Who is sponsoring clinical trial NCT05576662?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.